Biogen (BIIB) PT Lowered to $213 at RBC Capital
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $199.71 --0%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 15
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 15
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $213.00 (from $233.00) while maintaining a rating.
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Douglas AG (DOU:GR) PT Lowered to EUR14 at Berenberg
- Needham Reiterates Buy Rating on Biogen (BIIB)
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
